SGS has signed an agreement with AstraZeneca for the provision of safety, quality control and analytical testing services in support of AZD1222—a COVID-19 vaccine candidate co-invented by the University of Oxford and its spin-out company, Vaccitech and licensed by AstraZeneca.   SGS will conduct vaccine bulk harvest and drug substance testing from its Biosafety Center of Excellence in Glasgow, Scotland. The recently expanded laboratory provides testing of cell banks, vaccines, gene and cell ther...